Market Overview

This Small-Cap Vaccine Company Offers 14.5% Upisde, Vetr Crowd Says

Related NVAX
Benzinga's Top Upgrades, Downgrades For January 28, 2019
21 Stocks Moving In Friday's Pre-Market Session
Most Active Equity Options And Strikes For Midday - Thursday, Feb. 21 (TalkMarkets)

Shares of small cap clinical-stage vaccine company Novavax, Inc. (NASDAQ: NVAX) have lost more than 14.5 percent since the beginning of the year. However, since mid-May lows, the stock has managed to recuperate more than 65.5 percent of its value.

Nonetheless, the Vetr crowd seems to believe there is still room for upside left, as evidenced by its average price target of $8.66. This implies a potential return of more than 14.6 percent from current valuations.

Related Link: Here's How Crowdsourced Ratings Can Beat The Market

Seeking to better reflect this upside potential, the Vetr community decided upgrade its rating on shares of Novavax on Wednesday, from 4.0 Stars (Buy) to 4.5 Stars (Strong Buy) - out of a possible 5.0 Stars rating.

It should be noted that, in accordance with the new rating, 71 percent of the crowd’s ratings are bullish.

Latest Ratings for NVAX

Jan 2019H.C. WainwrightInitiates Coverage OnBuy
Dec 2018OppenheimerInitiates Coverage OnOutperform
Nov 2018PiperJaffrayUpgradesNeutralOverweight

View More Analyst Ratings for NVAX
View the Latest Analyst Ratings

Posted-In: VetrUpgrades Price Target Crowdsourcing Analyst Ratings General


Related Articles (NVAX)

View Comments and Join the Discussion!

How The Rise Of Creative Digital Has Led To A Major M&A Movement

You Can Now Hold Adobe, Vetr Crowd Says